相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Gastroenterology & Hepatology
Huiyul Park et al.
Summary: This study investigated the proportion of subjects with metabolic dysfunction-associated fatty liver disease (MAFLD) and assessed the fibrosis and cardiovascular risk in metabolically healthy MAFLD subjects. The results showed that 26.6% of MAFLD subjects were metabolically healthy and had comparable fibrosis burden and cardiovascular risk to the healthy control group.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Jing Zeng et al.
Hepatobiliary & Pancreatic Diseases International
(2022)
Article
Gastroenterology & Hepatology
William Kemp et al.
Summary: The study found a higher prevalence of metabolic-associated fatty liver disease (MAFLD) compared to non-alcoholic fatty liver disease (NAFLD) in a well-defined cohort, with the increased prevalence of MAFLD primarily driven by the presence of dual etiologies of liver disease. All participants classified as NAFLD also met the new definition of MAFLD.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Nutrition & Dietetics
Ehsaneh Taheri et al.
Summary: The study found that higher balances of pro- relative to anti-inflammatory dietary and lifestyle exposures may be associated with higher MAFLD risk among adults, suggesting that inflammation may be the primary mechanism through which diet affects MAFLD risk.
JOURNAL OF NUTRITION
(2022)
Article
Environmental Sciences
Qianli Yuan et al.
Summary: The prevalence and risk factors of metabolic-associated fatty liver disease (MAFLD) among adults in Beijing were investigated in this study. The results showed that the prevalence of MAFLD in Beijing adults was 32.40%, and risk factors such as male gender, older age, lower education, and urban residence were independently associated with MAFLD. Furthermore, even lean/normal-weight individuals were found to be at risk of developing MAFLD.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2022)
Article
Oncology
Tong Mu et al.
Summary: This study revealed the relationship between single nucleotide polymorphism (SNP) of PNPLA3, TM6SF2, MBOAT7, GATAD2A, and STAT3 genes and metabolism-related fatty liver disease (MAFLD). Several genotypes were found to be associated with the occurrence of MAFLD.
JOURNAL OF ONCOLOGY
(2022)
Article
Gastroenterology & Hepatology
Laurens A. van Kleef et al.
Summary: Research on a large population found that metabolic dysfunction-associated fatty liver disease (MAFLD) is more strongly associated with liver disease progression, including fibrosis and higher liver stiffness, while non-alcoholic fatty liver disease (NAFLD) shows no significant correlation with these indicators.
Article
Endocrinology & Metabolism
Xiaomo Wang et al.
Summary: MAFLD is associated with increased all-cause mortality among the Chinese population, and the risk is influenced by factors such as overweight/obesity, diabetes, other metabolic indicators, and second causes. Management of MAFLD patients should consider metabolic indicators and second causes for precise treatment and management.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Gastroenterology & Hepatology
Ji Hye Huh et al.
Summary: Obesity, rather than metabolic abnormalities, is the principal determinant of severe hepatic steatosis and fibrosis in patients with MAFLD.
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL
(2022)
Article
Gastroenterology & Hepatology
Zobair M. Younossi et al.
Summary: This study compared the long-term outcomes of NAFLD and MAFLD and found that they have similar clinical profiles and long-term prognosis. Insulin resistance is a predictor of liver mortality in NAFLD, while alcohol-associated liver disease (ALD) is the primary driver of mortality in MAFLD.
Article
Pediatrics
Maddi Oses et al.
Summary: This study aimed to develop a non-invasive and accurate prediction protocol for the identification of MAFLD among children with overweight/obesity. By measuring blood biochemical parameters and determining candidate SNPs, a prediction protocol with high sensitivity and specificity was developed.
Article
Gastroenterology & Hepatology
Ya-Cong Zhang et al.
Summary: This study demonstrated the validity of MAFLD subtype and fibrosis score in stratifying the risk of FLD patients using a representative sample of the US population. These findings can guide the determination of surveillance options for FLD patients.
HEPATOLOGY INTERNATIONAL
(2022)
Article
Gastroenterology & Hepatology
Stefano Ciardullo et al.
Summary: This study aimed to evaluate the prevalence of MAFLD among US adolescents and investigate whether the new MAFLD definition can identify individuals with more advanced liver disease. The study found that most US adolescents with elastographic evidence of steatosis meet the criteria for MAFLD, but these criteria do not appear to improve the detection of subjects with more advanced liver disease.
HEPATOLOGY COMMUNICATIONS
(2022)
Article
Gastroenterology & Hepatology
Zobair M. Younossi et al.
Summary: The article discusses the proposal to rename NAFLD to MAFLD, highlighting the shortcomings of the new term and warning that changing the name without a comprehensive understanding may have negative implications for the field. The recommendation is to establish a true international consensus group to assess the impact and consequences of the terminology change and make recommendations based on available evidence to move the field forward.
Article
Gastroenterology & Hepatology
Shang-Chin Huang et al.
Summary: The study examined and compared the clinical and histologic features of MAFLD versus NAFLD in patients with biopsy-proven hepatic steatosis. Results showed that MAFLD patients exhibited a higher degree of disease severity, and advanced fibrosis was associated with hepatitis B virus infection and metabolic diseases.
Article
Gastroenterology & Hepatology
Vy H. Nguyen et al.
Summary: The study found that individuals meeting the criteria for MAFLD had more comorbidities and worse prognosis compared to those with NAFLD only. Non-NAFLD MAFLD participants had the highest cumulative incidence of all-cause mortality, followed by NAFLD-MAFLD and non-MAFLD NAFLD participants. The MAFLD criteria should be considered in the general population to identify high-risk groups for early interventions.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Vincent Wai-Sun Wong et al.
Summary: The new definition of MAFLD does not significantly change the prevalence compared with NAFLD, but it may reduce the incidence by 25%. People with hepatic steatosis but not fulfilling the definition of MAFLD unlikely have significant liver disease.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Masato Yoneda et al.
Summary: The study found that the incidence rate of CVD increased significantly in NAFLD or MAFLD patients, and the proportion of diabetes mellitus and hypertriglyceridemia among them is also high, which may affect the development of CVD.
JOURNAL OF GASTROENTEROLOGY
(2021)
Review
Gastroenterology & Hepatology
Nahum Mendez-Sanchez et al.
Summary: The Latin American Association for the Study of the Liver aims to promote liver health and quality patient care, with a recent focus on fatty liver disease associated with metabolic dysfunction. A consensus was reached to rename the disease as metabolic-associated fatty liver disease and to diagnose it using a set of simple criteria. This change is expected to improve disease awareness and advancements in various aspects of the disease.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2021)
Review
Gastroenterology & Hepatology
Gamal Shiha et al.
Summary: Fatty liver disease associated with metabolic dysfunction is a global health problem, particularly prevalent in the Middle East and North Africa. The current nomenclature and diagnostic criteria for the disease have raised concerns among experts, leading to a proposal to rename it as metabolic-associated fatty liver disease (MAFLD) and diagnose it by positive criteria. Recommendations are being made to work with authorities in the region to implement these changes and improve healthcare for patients.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Stefano Ciardullo et al.
Summary: Limited data are available on the epidemiological implications of renaming NAFLD to MAFLD. A cross-sectional study using NHANES data found similar prevalence rates of NAFLD and MAFLD in the general US population, with a high agreement between the two definitions and higher rates among Hispanic individuals. Additionally, patients with either NAFLD or MAFLD showed similar risk of advanced liver fibrosis.
LIVER INTERNATIONAL
(2021)
Article
Multidisciplinary Sciences
Madunil Anuk Niriella et al.
Summary: This study compared the impact of NAFLD and MAFLD on health outcomes and found that the risks of new-onset metabolic traits and cardiovascular events were similar between the two during a 7-year follow-up. Individuals excluded by the NAFLD definition but captured by the MAFLD definition showed a higher risk of adverse outcomes compared to those excluded by the MAFLD definition but captured by the NAFLD definition.
Article
Medicine, General & Internal
Nadia Panera et al.
Summary: The study showed that the KLB rs17618244 variant is associated with hepatic fibrosis, inflammation, and cirrhosis mainly in obese adult patients with MAFLD. Additionally, hepatic stellate cells (HSCs) carrying this mutation exhibit enhanced proliferative rates and acquire a myofibroblast-like phenotype.
Article
Health Care Sciences & Services
Jiaofeng Huang et al.
Summary: This study found that MAFLD patients diagnosed with different numbers of metabolic conditions tended to be older, more likely to be female, and had more severe renal impairment and liver fibrosis. Additionally, MAFLD patients diagnosed with fewer metabolic conditions were more likely to have excessive alcohol consumption. Among patients diagnosed with a single metabolic condition, those with diabetes alone had the highest risk.
RISK MANAGEMENT AND HEALTHCARE POLICY
(2021)
Article
Gastroenterology & Hepatology
Yu-ling Chen et al.
Summary: MAFLD is prevalent in China and varies considerably among different age, sex, BMI, and female menopausal status groups. MAFLD is related to metabolic disorders, especially obesity, while metabolic disorders also play important roles in the occurrence of MAFLD in nonobese individuals. MAFLD patients exhibit a high prevalence of metabolic syndrome, dyslipidaemia, hyperuricaemia, and elevated liver enzymes. MAFLD tends to coexist with systemic metabolic disorders, and a deep inner relationship may exist between MAFLD and metabolic syndrome. Metabolic disorders should be considered to improve the management of MAFLD.
BMC GASTROENTEROLOGY
(2021)
Article
Medicine, General & Internal
Huiyul Park et al.
Summary: With the proposal of the new MAFLD definition, the added population (MAFLD-only group) shows a higher metabolic and fibrosis burden compared to those in the missed population (NAFLD-only group).
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Tsubasa Tsutsumi et al.
Summary: The study found that MAFLD patients had a higher risk of worsening ASCVD compared to NAFLD patients. The superiority of MAFLD was attributed to metabolic dysfunction rather than moderate alcohol consumption.
HEPATOLOGY RESEARCH
(2021)
Article
Gastroenterology & Hepatology
Donghee Kim et al.
Summary: This study demonstrated that metabolic dysfunction-associated fatty liver disease (MAFLD) was associated with an increased risk of all-cause mortality in US adults, while non-alcoholic fatty liver disease (NAFLD) showed no association with all-cause mortality after adjusting for metabolic risk factors. Individuals who met the criteria for MAFLD but not NAFLD had a higher risk of all-cause mortality.
JOURNAL OF HEPATOLOGY
(2021)
Article
Nutrition & Dietetics
Jiahua Fan et al.
Summary: This study in South China found a high prevalence of MAFLD, with risk factors including overweight/obesity, type 2 diabetes, and metabolic dysregulation. High physical activity and moderate consumption of soups may be protective factors against MAFLD.
NUTRITION & METABOLISM
(2021)
Article
Medicine, General & Internal
Qi Huang et al.
Summary: The study found that participants with MAFLD or NAFLD were highly concordant, with MAFLD showing a greater overall mortality risk compared to NAFLD, but equal risk for cause-specific mortality. The new terminology excluded participants with lower mortality risk and included those with higher risk.
FRONTIERS IN MEDICINE
(2021)
Article
Environmental Sciences
Francesco Baratta et al.
Summary: Applying the MAFLD criteria to a cohort of dysmetabolic patients with NAFLD led to a significant overlap between the NAFLD and MAFLD diagnoses, with specific subgroups such as lean NAFLD patients being excluded by the new MAFLD definition.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2021)
Article
Gastroenterology & Hepatology
Mohammed Eslam et al.
JOURNAL OF HEPATOLOGY
(2020)
Article
Gastroenterology & Hepatology
Su Lin et al.
LIVER INTERNATIONAL
(2020)
Article
Gastroenterology & Hepatology
Mohammed Eslam et al.
HEPATOLOGY INTERNATIONAL
(2020)
Article
Gastroenterology & Hepatology
Sakura Yamamura et al.
LIVER INTERNATIONAL
(2020)
Review
Medicine, General & Internal
Guangrong Dai et al.
Review
Gastroenterology & Hepatology
Mohammed Eslam et al.
JOURNAL OF HEPATOLOGY
(2018)
